On Friday, Contineum Therapeutics Inc (NASDAQ: CTNM) opened higher 13.28% from the last session, before settling in for the closing price of $3.84. Price fluctuations for CTNM have ranged from $3.35 to $21.66 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -7.75% at the time writing. With a float of $13.50 million, this company’s outstanding shares have now reached $19.14 million.
In an organization with 41 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 25.21%, operating margin of -24410.74%, and the pretax margin is -20591.32%.
Contineum Therapeutics Inc (CTNM) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Contineum Therapeutics Inc is 47.82%, while institutional ownership is 43.16%. The most recent insider transaction that took place on Nov 25 ’24, was worth 16,177. In this transaction Chief Scientific Officer of this company sold 1,010 shares at a rate of $16.02, taking the stock ownership to the 168,562 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Chief Scientific Officer sold 6,190 for $16.38, making the entire transaction worth $101,421. This insider now owns 169,572 shares in total.
Contineum Therapeutics Inc (CTNM) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -7.75% per share during the next fiscal year.
Contineum Therapeutics Inc (NASDAQ: CTNM) Trading Performance Indicators
Check out the current performance indicators for Contineum Therapeutics Inc (CTNM). In the past quarter, the stock posted a quick ratio of 21.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -2.83 in one year’s time.
Technical Analysis of Contineum Therapeutics Inc (CTNM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.61 million. That was better than the volume of 0.12 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.75%.
During the past 100 days, Contineum Therapeutics Inc’s (CTNM) raw stochastic average was set at 21.53%, which indicates a significant decrease from 91.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.26 in the past 14 days, which was lower than the 0.49 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.06, while its 200-day Moving Average is $9.49. However, in the short run, Contineum Therapeutics Inc’s stock first resistance to watch stands at $4.55. Second resistance stands at $4.76. The third major resistance level sits at $5.10. If the price goes on to break the first support level at $4.00, it is likely to go to the next support level at $3.66. Assuming the price breaks the second support level, the third support level stands at $3.45.
Contineum Therapeutics Inc (NASDAQ: CTNM) Key Stats
There are currently 25,872K shares outstanding in the company with a market cap of 112.54 million. Presently, the company’s annual sales total 0 K according to its annual income of -42,260 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -15,990 K.
